...RESSMAN THOMAS MASSIE

### VACCINE DOES NOT STOP SPREAD OF L

MR. GOHMERT

### THE LONG-CHAMBERS AEROSPACE SAFETY PROTOCOL INITIATIVE

Post Mandated mRNA Therapy Screening Tool for Aviators and Crew



MR. MASSI

## BOTTOM LINE UP FRONT

Despite the overwhelming evidence and documented injuries and questionable deaths recently, post roll out of the COVID 19 Vaccination Program and subsequent mandates, serious political debates and stonewalling have only resulted in turning friendly skies into dangerous skies.

For the purpose of this initiative, we shall define "vaccine" as being the biological gene modification agents.

The collective endeavors of world leaders in aviation safety and medical expertise have led to;

**AVIATION** 

SAFETY

**1**) Creation of the LONG-CHAMBERS AEROSPACE SAFETY PROTOCOL INITIATIVE, effectively screening pilots and crew post COVID vaccines

2) Emphasis on the need to continue the safe and effective practice of self reporting under the voluntary Flight Operational Quality Assurance (FOQA) program.

## AVIATION SAFETY

### ABSTRACT

Safety within professional aviation has vastly improved over the past several decades. This is due in large part to a culture founded upon open communication and selfdisclosure of errors or negative safety trends. Consider the voluntary Flight Operational Quality Assurance (FOQA) program.

This requires active participation from all flight crew to be effective. Pilots are trained to be careful analysts of their environment, recognizing risks and actively mitigating.

For many, their training and differential risk analysis led to concerns and negative conclusions regarding the compatibility of Covid-19 vaccination with health and flight safety.



## A SOLUTION

"The practice of medicine is an art, not an algorithm."
In the zero-defect environment of aviation medicine, failure is not an option."

LTC (Ret.) Peter Constantine Chambers, D.O. Special Operations Flight Surgeon, Green Beret

# **THE REGS**

**Current COVID 19 Vaccine Considerations** 

### **AME Guidelines State the Following:**

**Do Not Issue.** "AMEs should not issue airmen medical certificates to applicants who are using these or classes of medications."

**FDA (Food and Drug Administration) approved less than 12 months ago.** The FAA generally requires at least one-year of post-marketing experience with a new drug before consideration for aeromedical certification purposes. This observation period allows time for uncommon, but aeromedically significant, adverse effects to manifest themselves. Contact either your Regional Flight Surgeon or AMCD for guidance on specific applicants or to request consideration for a particular medication

See: <a href="https://www.faa.gov/ame\_guide/pharm/dni\_dnf">https://www.faa.gov/ame\_guide/pharm/dni\_dnf</a>



**Current COVID 19 Vaccine Considerations** 

Individuals holding an FAA-issued Airman Medical Certificate or Medical Clearance are reminded that they are prohibited from performing flight crewmember duties or air traffic control duties if they do not meet medical certification requirements, including those related to adverse events from medications that render them unable to perform such duties.

14CFR61.53 applies to all certificated pilots whether they hold a medical certificate or not.

AAM continues to monitor the situation and will adjust this policy as necessary to ensure aviation safety.



**Current COVID 19 Vaccine Considerations** 


The Federal Air Surgeon determined that FAA medical certificate holders may not act as pilot in command, or in any other capacity as a required flightcrew member, for 48 hours after each dose of the Pfizer-BioNTech, Moderna, and Johnson & Johnson vaccines. The Federal Air Surgeon made this determination after evaluation of available medical information about these COVID-19 vaccines and potential side effects. As a result of this determination and consistent with 14 CFR § 61.53(a), each person subject to part 67 who receives the vaccine must wait 48 hours after each dose before acting as pilot in command or as a required flightcrew member.

In the event that an FAA medical certificate holder experiences side effects after the 48-hour period has elapsed, the medical certificate holder may not act as pilot in command, or in any other capacity as a required flightcrew member as described at  $14 \text{ CFR } \S 61.53(a)$  for the duration of the symptoms.

# **THE RISKS**

**Current COVID 19 Vaccine Considerations** 

Per Worldwide Safety report issued by Pfizer 28 February 2021, (5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021) cumulative analysis report revealed ADVERSE EVENTS (AE), summarized as follows:



# **THE RISKS**

**Current COVID 19 Vaccine Considerations** 

Table 7.

Per Worldwide Safety report issued by Pfizer 28 February, 2021, (5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021) cumulative analysis report revealed ADVERSE EVENTS of SPECIAL INTEREST (AESI),

summarized as follows:

Table 7. ALSIS Evaluation	
AESIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>
Category	Total Number of Cases (N=42086)
Anaphylactic Reactions Search criteria: Anaphylactic reaction SMQ (Narrow and Broad, with the algorithm applied), selecting relevant cases according to BC criteria Cardiovascular AESIs	<ul> <li>Please refer to the Risk 'Anaphylaxis' included above in Table 4.</li> <li>Number of cases: 1403 (3.3% of the total PM dataset), of which</li> </ul>
Search criteria: PTs Acute myocardial infarction; Arrhythmia; Cardiac failure; Cardiac failure acute; Cardiogenic shock; Coronary artery disease; Myocardial infarction; Postural orthostatic tachycardia syndrome; Stress cardiomyopathy; Tachycardia	<ul> <li>241 are medically confirmed and 1162 are non-medically confirmed;</li> <li>Country of incidence: UK (268), US (233), Mexico (196), Italy (141), France (128), Germany (102), Spain (46), Greece (45), Portugal (37), Sweden (20), Ireland (17), Poland (16), Israel (13), Austria, Romania and Finland (12 each), Netherlands (11), Belgium and Norway (10 each), Czech Republic (9), Hungary and Canada (8 each), Croatia and Denmark (7 each), Iceland (5); the remaining 30 cases were distributed among 13 other countries;</li> <li>Subjects' gender: female (1076), male (291) and unknown (36);</li> <li>Subjects' age group (n = 1346): Adult<sup>c</sup> (1078), Elderly<sup>d</sup> (266) Child<sup>e</sup> and Adolescent<sup>c</sup> (1 each);</li> <li>Number of relevant events: 1441, of which 946 serious, 495</li> </ul>
DISORDERS	<ul> <li>non-serious; in the cases reporting relevant serious events;</li> <li>Reported relevant PTs: Tachycardia (1098), Arrhythmia (102), Myocardial infarction (89), Cardiac failure (80), Acute myocardial infarction (41), Cardiac failure acute (11), Cardiogenic shock and Postural orthostatic tachycardia syndrome (7 each) and Coronary artery disease (6);</li> <li>Relevant event onset latency (n = 1209): Range from &lt;24 hours to 21 days, median &lt;24 hours;</li> </ul>

# **THE RISKS**

AE

### **Current COVID 19 Vaccine Considerations**

### ADVERSE EVENTS of SPECIAL INTEREST (AESI), continued:

AESIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>	AESIs <sup>a</sup>
Category	Total Number of Cases (N=42086)	
	Relevant event outcome <sup>5</sup> ; fatal (136), resolved/resolving (767), resolved with sequelae (21), not resolved (140) and unknown (380); Conclusion: This cumulative case review does not raise new safety	Category
	issues. Surveillance will continue	
COVID-19 AESIs Search criteria: Covid-19 SMQ (Narrow and Broad) OR PTs Ageusia; Anosmia	<ul> <li>Number of cases: 3067 (7.3% of the total PM dataset), of which 1013 are medically confirmed and 2054 are non-medically confirmed;</li> <li>Country of incidence: US (1272), UK (609), Germany (360), France (161), Italy (94), Spain (69), Romania (62), Portugal (51), Poland (50), Mexico (43), Belgium (42), Israel (41), Sweden (30),</li> </ul>	Haematol Search crii (HLT) (Pri Neutropen
ANOSMIA	Austria (27), Greece (24), Denmark (18), Czech Republic and Hungary (17 each), Canada (12), Ireland (11), Slovakia (9), Latvia and United Arab Emirates (6 each); the remaining 36 cases were distributed among 16 other different countries; Subjects' gender: female (1650), male (844) and unknown (573);	Path) OR I thrombocy Thrombocy Haemorrhu laboratory
	<ul> <li>Subjects' age group (n= 1880): Adult (1315), Elderly (560), Infant<sup>h</sup> and Adolescent (2 each), Child (1);</li> </ul>	
	<ul> <li>Number of relevant events: 3359, of which 2585 serious, 774 non-serious;</li> </ul>	BLC
	<ul> <li>Most frequently reported relevant PTs (&gt;1 occurrence): COVID-19 (1927), SARS-CoV-2 test positive (415), Suspected COVID-19 (270), Ageusia (228), Anosmia (194), SARS-CoV-2 antibbdy test negative (83), Exposure to SARS-CoV-2 (62), SARS-CoV-2 antibbdy test positive (53), COVID-19 preumonia (51), Asymptomatic COVID-19 (31), Coronavirus infection (13), Occupational exposure to SARS-CoV-2 (11), SARS-CoV-2 test false positive (7), Coronavirus test positive (6), SARS-CoV-2 test negative (3) SARS-CoV-2 antibody test (2);</li> <li>Relevant event onset latency (n = 2070): Range from &lt;24 hours to 374 days, median 5 days;</li> <li>Relevant event outcome: fatal (136), not resolved (547), resolved/resolving (558), resolved with sequelae (9) and unknown (2110).</li> </ul>	DIS
D LADOR	Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue	
Dermatological AESIs	<ul> <li>Number of cases: 20 cases (0.05% of the total PM dataset), of which 15 are medically confirmed and 5 are non-medically</li> </ul>	
Search criteria: PT Chillblains; Erythema multiforme	<ul> <li>confirmed;</li> <li>Country of incidence: UK (8), France and Poland (2 each), and the</li> </ul>	Hepatic A Search crit investigation
DERMATOLOGI	countries; Subjects' gender: female (17) male and unknown (1 each);	(SMQ) (Na PT Liver in
	<ul> <li>Subjects' genuer: remare (17) mare and unknown (1 each);</li> <li>Subjects' age group (n=19): Adult (18), Elderly (1);</li> </ul>	
	<ul> <li>Number of relevant events: 20 events, 16 serious, 4 non-serious</li> </ul>	

AESIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>
ategory	Total Number of Cases (N=42086)
	Reported relevant PTs: Erythema multiforme (13) and Chillblains (7) Relevant event onset latency (n = 18): Range from <24 hours to 17 days, median 3 days; Relevant event outcome: resolved/resolving (7), not resolved (8) and unknown (6). Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.
Haematological AESIs Search criteria: Leukopenias NEC HLD (Primary Path) OR Veutropenias (HLT) (Primary ath) OR PTS Immune Irrombocytopenia OR SMQ Haemorrhage terms (excl aboratory terms BLOOD DISORDERS	<ul> <li>Number of cases: 932 (2.2% of the total PM dataset), of which 524 medically confirmed and 408 non-medically confirmed;</li> <li>Country of incidence: UK (343), US (308), France (50), Germany (43), Italy (37), Spain (27), Mexico and Poland (13 each), Sweden (10), Israel (9), Netherlands (8), Denmark, Finland, Portugal and Ireland (7 each), Austria and Norway (6 each), Croatia (4), Greece, Belgium, Hungary and Switzerland (3 each), Cyprus, Latvia and Serbia (2 each); the remaining 9 eases originated from 9 different countries;</li> <li>Subjects' genet (m=898): female (676) and male (222);</li> <li>Subjects' genet (m=898): female (676) and male (222);</li> <li>Subjects' genet (m=898): female (676) and male (222);</li> <li>Subjects' age group (n=837): Adult (543), Elderly (293), Infant (1);</li> <li>Number of relevant events: 1080, of which 681 serious, 399 non-serious;</li> <li>Most frequently reported relevant PTs (≥15 occurrences) include: Epistaxis (127), Contusion (112), Vaccination site bruising (96), Vaccination site haemorrhage (51). Petechiae (50), Haematorhage (42), Haematochezia (34), Thrombocytopenia (33), Vaccination site haemorrhage (23), Nectah lamemorrhage (25), Eye haemorrhage (23), Rectah haemorrhage (25), Eye haemorrhage (23), Rottah lamemorrhagi (15).</li> <li>Relevant event outcome: fatal (34), resolved/resolvenia and Purpura (16 each) Diarrhoca haemorrhagi (15);</li> <li>Relevant event outcome: fatal (34), resolved/resolving (393), resolved with sequelae (17), not resolved (267) and unknown (371).</li> <li>Conclusion: This cumulative case review does not raise new safety</li> </ul>
Hepatic AESIs Search criteria: Liver related nvestigations, signs and symptoms SMQ (Narrow and Broad) OR	<ul> <li>issues. Surveillance will continue</li> <li>Number of cases: 70 cases (0.2% of the total PM dataset), of which 54 medically confirmed and 16 non-medically confirmed;</li> <li>Country of incidence: UK (19), US (14), France (7), Italy (5), Germany (4), Belgium, Mexico and Spain (3 each), Austria, and</li> </ul>
PT Liver injury	<ul> <li>Iceland (2 each); the remaining 8 cases originated from 8 different countries;</li> <li>Subjects' gender: female (43), male (26) and unknown (1);</li> <li>Subjects' age group (n=64): Adult (37), Elderly (27);</li> </ul>

and the second se	
ble 7. AESIs Evaluation for BNT162b2	
SIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>
tegory	Total Number of Cases (N=42086)
LIVER DISEASE	<ul> <li>Number of relevant events: 94, of which 53 serious, 41 non-serious;</li> <li>Most frequently reported relevant PTs (≥3 occurrences) include: Alanine aminotransferase increased (16), Transaminases increased and Hepatic pain (9 each), Liver function test increased (8), Aspartate aminotransferase increased and Liver function test increased and (7 each), Gamma-glutamyltransferase increased and Hepatic enzyme increased (6 each), Blood alkaline phosphatase increased and Liver framasminasemini (3 each);</li> <li>Relevant event onset latency (n = 57): Range from &lt;24 hours to 20 days, median 3 days;</li> <li>Relevant event outcome: fatal (5), resolved/resolving (27), resolved with sequelae (1), not resolved (14) and unknown (47).</li> </ul>
	Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue
cial Paralysis Irch criteria: PTs Facial alysis, Facial paresis	<ul> <li>Number of cases: 449<sup>(1,07%</sup> of the total PM dataset), 314 medically confirmed and 135 non-medically confirmed;</li> <li>Country of incidence: US (124), UK (119), Italy (40), France (27), Israel (20), Spain (18), Germany (13), Sweden (11), Ireland (9), Cyprus (8), Austria (7), Finland and Portugal (6 each), Hungary and Romania (5 each), Croatia and Mexico (4 each), Canada (3),Czech Republic, Malta, Netherlands, Norway, Poland and Puerto Rico (2 each), Camatia and Mexico (4 each), Canada (3),Czech Republic, Malta, Netherlands, Norway, Poland and Puerto Rico (2 each), the remaining 8 cases originated from 8 different countries;</li> <li>Subjects' gender: female (295), male (133), unknown (21);</li> <li>Subjects' age group (n=411): Adult (313), Elderly (96), Infanti and Child (1 each);</li> <li>Number of relevant events<sup>3</sup>: 453, of which 399 serious, 54 non-serious;</li> <li>Reported relevant PTs: Facial paralysis (401), Facial paresis (64);</li> <li>Relevant event onset latency (n = 404): Range from &lt;24 hours to 46 days, median 2 days;</li> <li>Relevant event outcome: resolved/resolving (184), resolved with sequelae (3), not resolved (183) and unknown (97);</li> </ul>
	Overall Conclusion: This cumulative case review does not raise ne safety issues. Surveillance will continue. Causality assessment will further evaluated following availability of additional unblinded dat from the clinical study (459)101, which will be unblinded for fine analysis approximately mid-April 2021. Additionally, non- interventional post-authorisation safety studies, C4591011 and C4591012 are expected to capture data on a sufficiently large vaccinated population to detect an increased risk of Bell's palsy in vaccinated individuals. The timeline for conducting these analyses be established based on the size of the vaccinated population captu

dy data sources by the first interim reports (due

# **THE RISKS**

### **Current COVID 19 Vaccine Considerations**

### ADVERSE EVENTS of SPECIAL INTEREST (AESI), continued:

AESIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>
Category	Total Number of Cases (N=42086)
	2021). Study C4591021, pending protocol endorsement by EMA, is also intended to inform this risk.
Immune-Mediated/Autoimmune AESIs Search criteria: Immune- mediated/autoimmune disorders (SMQ) (Broad and Narrow) OR Autoimmune disorders HIGT (Primary Path) OR PTs Cytokine release syndrome; Cytokine storm; Hypersensitivity	<ul> <li>Number of cases: 1050 (2.5 % of the total PM dataset), of whic 760 medically confirmed and 290 non-medically confirmed;</li> <li>Country of incidence (&gt;10 cases): UK (267), US (257), Italy (7 France and Germany (69 each), Mexico (36), Sweden (35), Spa (32), Greece (31), Israel (21), Denmark (18), Portugal (17), Austria and Czech Republic (16 each), Canada (12), Finland (17), Finland (17), Finland (18), Sortigue (156).</li> <li>Subjects' gender (m-682): female (250), male (156).</li> <li>Subjects' gender (m-682): female (250), male (156).</li> <li>Subjects' age group (n=944): Adult (746), Elderly (196), Adolescent (2).</li> <li>Number of relevant events: 1077, of which 780 serious, 297 non-serious.</li> <li>Most frequently reported relevant PTs (&gt;10 occurrences): Hypersensitivity (596), Neuropathy peripheral (49), Pericarditi (32), Myocarditis (25), Dermatitis (24), Diabetes mellitus and Encephaltis (16 each), Psoriasis (14), Dermatitis Bullous (13), Autoimmune disorder and Raynaud's phenomenon (11 each);</li> <li>Relevant event outcome!: resolved/resolving (517), not resolved (215), fatal (12), resolved with sequelae (22) and unknown (31);</li> </ul>
	Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue
Musculoskeletal AESIs Search criteria: PTs Arthralgia; Arthritis, Arthritis bacterial <sup>a</sup> ; Chronic fatigue syndrome; Polyarthritis, Polyneuropathy; Post viral fatigue syndrome; Rheumatoid arthritis	Number of cases: 3600 (8.5% of the total PM dataset), of whicl 2045 medically confirmed and 1555 non-medically confirmed; Country of incidence: UK (1406), US (1004), Haly (285), Mex (236), Germany (72), Portugal (70), France (48), Greece and Poland (46), Latvia (33), Czech Republic (32), Israel and Spair (26), Sweden (25), Romania (24), Denmark (23), Finland and Ireland (19 each), Austria and Belgium (18 each), Canada (16), Netherlands (14), Bulgaria (12), Croatia and Serbia (9 each), Cyprus and Hungary (8 each), Norway (7), Estonia and Puerto Rico (6 each), Iceland and Lithuania (4 each); the remaining 21 cases originated from 11 different countries;
MUSCULO- SKELETAL DISORDERS	<ul> <li>Subjects' gender (n=3471): female (2760), male (711);</li> <li>Subjects' age group (n=3372): Adult (2850), Elderly (515), Ch (4), Adolescent (2), Infant (1);</li> <li>Number of relevant events: 3640, of which 1614 serious, 2026 non-serious;</li> <li>Reported relevant PTs: Arthralgia (3525), Arthritis (70), Rheumatoid arthritis (26), Polyarthritis (5), Polyneuropathy, Pe viral fatigue syndrome, Chronic fatigue syndrome (4 each), Arthritis bacterial (1);</li> </ul>

Fable 7.         AESIs Evaluation for BNT162b2	
AESIs*	Post-Marketing Cases Evaluation <sup>b</sup>
Category	Total Number of Cases (N=42086)
	Relevant event outcome: resolved/resolving (1801), not resolved (959), resolved with sequelae (49), and unknown (853).     Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue.
Neurological AESIs (including demyelination) Search criteria: Convulsions (SMQ) (Broad and Narrow) OR Demyelination (SMQ) (Broad and Narrow) OR PTs Attaxia; Cataplexy: Encephalopathy; Fibromyalgia; Intracranial oressure increased: Meningitis; Meningitis aseptic; Narcolepsy NEURO- LOGICAL DISORDERS	<ul> <li>Number of cases: 501 (1.2% of the total PM dataset), of which 365 medically confirmed and 136 non-medically confirmed.</li> <li>Ountry of incidence (2+0 case): UK (157), US (68), Germany (49), Mexico (35), Italy (31), France (25), Spain (18), Poland (17), Netherlands and Israel (15 cach), Sweden (9). The remaining 71 cases were from 22 different countries.</li> <li>Subjects' gender (n=478): Emale (328), male (150).</li> <li>Subjects' age group (n=478): Adult (329), Elderly (149);</li> <li>Number of relevant events: 542, of which 515 serious, 27 non-serious.</li> <li>Most frequently reported relevant PTs (&gt;2 occurrences) included: Seizure (204), Epilepsy (83), Generalised tonic-clonic seizure (33), Guillain-Barre syndrome (24), Fibromyalgia and Triggeninal neuralgia (17 each), Febrile convulsion, (15), Status epilepticus (12), Aura and Myelitis transverse (11 each), Multiple sclerosis relapse and Optic neuritis (10 each), Petit mal epilepsy and Tonic convulsion (9 each), Ataxia (8), Encephalopathy and Tonic clonic movements (7 each), Fostical state, Seizure like phenomena and Tongue Using (16 each), Bad sensation, Demyelination, Meningitis, Postical state, Seizure like phenomena and Tongue Using (16 each);</li> <li>Relevant event onset latency (n = 423): Range from &lt;24 hours to 48 days, median 1 day;</li> <li>Relevant events outcome: fatal (16), resolved/resolving (265), resolved with sequelae (13), not resolved (89) and unknown (161);</li> </ul>
Other AESIs Search criteria: Herpes viral Infections (IILT) (Primary Path) OR PTs Adverse event following immunisation; Inflammation; Manufacturing laboratory analytical testing issue; Manufacturing production issue; Manufacturing production issue; Manufacturing production issue; Manufacturing production issue; MaleES-CoV test positive; Middle East respiratory syndrome; Multiple organ dysfunction syndrome; Occupational exposure	<ul> <li>Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue</li> <li>Number of cases: 8152 (19.4% of the total PM dataset), of which 4977 were medically confirmed and 3175 non-medically confirmed;</li> <li>Country of incidence (&gt; 20 occurrences): UK (2715), US (2421), Italy (710), Mexico (223), Portugal (210), Germany (207), France (186), Spain (183), Sweden (133), Denmark (127), Poland (120), Greece (95), Israel (79), Czech Republic (76), Romania (57), Hungary (53), Finland (52), Norway (51), Latvia (49), Austria (47), Croatia (42), Belgium (41), Canada (39), Ireland (24), Serbia (28), Iceland (25), Netherlands (22). The remaining 127 cases were from 21 different countries;</li> <li>Subjects' gender (n=7829); female (5969), male (1860);</li> <li>Subjects' age group (n=7479): Adult (6330), Elderly (1125), Adolescent, Child (9 each), Infant (6);</li> </ul>

#### Table 7. AESIs Evaluation for BNT162b2

AESIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>
Category	Total Number of Cases (N=42086)
isolation; Product availability issue; Product distribution issue; Product supply issue; Pyrexia; Quarantine; SARS-CoV-1 test; SARS-CoV-1 test negative; SARS- CoV-1 test positive	<ul> <li>Number of relevant events: 8241, of which 3674 serious, 4568 non-serious;</li> <li>Most frequently reported relevant PTs (≥6 occurrences) included: Pyrexia (7666), Herpes zoster (259), Inflammation (132), Oral herpes (80), Multiple organ dysfunction syndrome (18), Herpes virus infection (17), Herpes simplex (13), Ophthalmic herpes zoster (10), Herpes ophthalmic and Herpes zoster reactivation (6 each);</li> <li>Relevant event onset latency (n =6836): Range from &lt;24 hours to 61 days, median 1 day;</li> <li>Relevant event outcome: fatal (96), resolved/resolving (5008), resolved with sequelae (84), not resolved (1429) and unknown (1685).</li> <li>Conclusion: This cumulative case review does not raise new safety issues. Surveilance will continue</li> </ul>
Pregnancy Related AESIs	For relevant cases, please refer to Table 6, Description of Missing
Search criteria: PTs Amniotic cavity infection; Caesarean section; Congenital anomaly; Death neonatal; Eclampsia; Foetal distress syndrome; Low birth weight baby; Maternal exposure during pregnancy; Placenta praevia; Pre-eclampsia; Premature labour; Stillbirth; Uterine rupture; Vasa praevia	Information, Use in Pregnancy and While Breast Feeding
Renal AESIs Search criteria: PTs Acute kidney injury: Renal failure. KIDNEY DISORDERS	<ul> <li>Number of cases: 69 cases (0.17% of the total PM dataset), of which 57 medically confirmed, 12 non-medically confirmed, 13 non-medically confirmed, 12 non-me</li></ul>
Respiratory AESIs Search criteria: Lower respiratory tract infections NEC (HLT)	<ul> <li>Surveillance will continue.</li> <li>Number of cases: 130 cases (0.3% of the total PM dataset), of which 107 medically confirmed;</li> </ul>

# **THE RISKS**

### **Current COVID 19 Vaccine Considerations**

### ADVERSE EVENTS of SPECIAL INTEREST (AESI), continued:

AFSIC

Table 7. AESIs Evaluation for BNT162b2

#### AESIs Evaluation for BNT162b2 Table 7. **AESIs**<sup>a</sup> Post-Marketing Cases Evaluation Category Total Number of Cases (N=42086) (Primary Path) OR Respiratory Countries of incidence: United Kingdom (20), France (18), United failures (excl neonatal) (HLT) States (16), Germany (14), Spain (13), Belgium and Italy (9), (Primary Path) OR Viral lower Denmark (8), Norway (5), Czech Republic, Iceland (3 each); the respiratory tract infections (HLT) remaining 12 cases originated from 8 different countries. (Primary Path) OR PTs: Acute Subjects' gender (n=130): female (72), male (58). respiratory distress syndrome; Subjects's age group (n=126): Elderly (78), Adult (47), Endotracheal intubation; Hypoxia Adolescent (1). Pulmonary haemorrhage; Number of relevant events: 137, of which 126 serious, 11 Respiratory disorder; Severe acute non-serious respiratory syndrome Reported relevant PTs: Respiratory failure (44), Hypoxia (42), Respiratory disorder (36), Acute respiratory distress syndrome (10), Chronic respiratory syndrome (3), Severe acute respiratory syndrome (2) Relevant event onset latency (n=102): range from < 24 hours to 18 RESPIRATORY days, median 1 day; Relevant events outcome: fatal (41), Resolved/resolving (47), not DISORDERS recovered (18) and unknown (31). Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue Thromboembolic Events Number of cases: 151 (0.3% of the total PM dataset), of which 111 medically confirmed and 40 non-medically confirmed; Search criteria: Embolism and Country of incidence: UK (34), US (31), France (20), Germany thrombosis (HLGT) (Primarv Path), excluding PTs reviewed as (15), Italy and Spain (6 each), Denmark and Sweden (5 each), Stroke AESIs, OR PTs Deep vein Austria, Belgium and Israel (3 each), Canada, Cyprus, Netherlands thrombosis: Disseminated and Portugal (2 each); the remaining 12 cases originated from 12 different countries; intravascular coagulation: Subjects' gender (n= 144): female (89), male (55); Embolism: Embolism venous: Pulmonary embolism Subjects' age group (n=136): Adult (66), Elderly (70); Number of relevant events: 168, of which 165 serious, 3 non-serious Most frequently reported relevant PTs (>1 occurrence) included: Pulmonary embolism (60), Thrombosis (39), Deep vein thrombosis (35), Thrombophlebitis superficial (6), Venous CLOTTING thrombosis limb (4), Embolism, Microembolism, Thrombophlebitis and Venous thrombosis (3 each) Blue toe **DISORDERS** / syndrome (2); Relevant event onset latency (n = 124): Range from <24 hours to 28 days, median 4 days; PULMONARY Relevant event outcome: fatal (18), resolved/resolving (54), resolved with sequelae (6), not resolved (49) and unknown (42). **EMBOLI** Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue Stroke Number of cases: 275 (0.6% of the total PM dataset), of which Search criteria: HLT Central 180 medically confirmed and 95 non-medically confirmed; Country of incidence: UK (81), US (66), France (32), Germany nervous system haemorrhages and cerebrovascular accidents (21), Norway (14), Netherlands and Spain (11 each), Sweden (9),

#### Category Total Number of Cases (N=42086) (Primary Path) OR HLT Israel (6), Italy (5), Belgium (3), Denmark, Finland, Poland and Cerebrovascular venous and sinus Switzerland (2 each); the remaining 8 cases originated from 8 thrombosis (Primary Path) different countries: Subjects' gender (n= 273): female (182), male (91); Subjects' age group (n=265): Adult (59), Elderly (205), Child\* (1): Number of relevant events: 300, all serious: Most frequently reported relevant PTs (>1 occurrence) included PTs indicative of Ischaemic stroke: Cerebrovascular accident (160), Ischaemic stroke (41), Cerebral infarction **CEREBRO-**(15), Cerebral ischaemia, Cerebral thrombosis, Cerebral venous sinus thrombosis, Ischaemic cerebral infarction and Lacunal infarction (3 each) Basal ganglia stroke. VASCULAR Cerebellar infarction and Thrombotic stroke (2 each); PTs indicative of Haemorrhagic stroke: Cerebral DISORDERS haemorrhage (26), Haemorrhagic stroke (11), Haemorrhage intracranical and Subarachnoid haemorrhage (5 each), Cerebral haematoma (4), Basal ganglia haemorrhage and Cerebellar haemorrhage (2 each): Relevant event onset latency (n = 241): Range from <24 hours to</li> 41 days, median 2 days; Relevant event outcome: fatal and resolved/resolving (61 each). resolved with sequelae (10), not resolved (85) and unknown (83). Conclusion: This cumulative case review does not raise new safety issues. Surveillance will continue Vasculitic Events Number of cases: 32 cases (0.08% of the total PM dataset), of Search criteria: Vasculitides HLT which 26 medically confirmed and 6 non-medically confirmed; Country of incidence: UK (13), France (4), Portugal, US and Spain (3 each), Cyprus, Germany, Hungary, Italy and Slovakia and Costa rica (1 each); Subjects' gender: female (26), male (6); Subjects' age group (n=31): Adult (15), Elderly (16); Number of relevant events: 34, of which 25 serious, 9 non-serious; VENOUS Reported relevant PTs: Vasculitis (14), Cutaneous vasculitis and Vasculitic rash (4 each), (3), Giant cell arteritis and Peripheral DISORDERS ischaemia (3 each), Behcet's syndrome and Hypersensitivity vasculitis (2 each) Palpable purpura, and Takayasu's arteritis (1 each): Relevant event onset latency (n = 25): Range from <24 hours to 19 days, median 3 days; Relevant event outcome: fatal (1), resolved/resolving (13), not resolved (12) and unknown (8). Conclusion: This cumulative case review does not raise new safety ssues. Surveillance will continue

Post-Marketing Cases Evaluation

#### Table 7. AESIs Evaluation for BNT162b2

AESIs <sup>a</sup>	Post-Marketing Cases Evaluation <sup>b</sup>
Category	Total Number of Cases (N=42086)
approval data sources; c. Subjects with age ranged betwee d. Subjects with age ranged betwee f. Subjects with age ranged betwee g. Multiple episodes of the same P cases hence the sum of the events ou h. Subjects with age ranged betwee i. Twenty-four additional cases we nerve palsy because they described o attack); 1 case was excluded from th yaccine, and had left postauricular ea- vaciation that had not resolved at k. If a case included both PT Facia considered in the descriptions of the l. Multiple episodes of the same P cases hence the sum of the events ou m. This UK case report received from the vaccine and had stroke (unknown	to evidence from post-EUA/conditional marketing authorisation en 18 and 64 years; ove 65 years; en 2 and 11 years; en 12 and less than 18 years; T event were reported with a different clinical outcome within some trome exceeds the total number of PT events; en 1 (28 days) and 23 months; ree excluded from the analysis as they were not cases of peripheral faci- ther disorders (stroke, cerebral haemorrhage or transient ischaemic e analysis because it was invalid due to an unidentifiable reporter; om the UK MHRA described a 1-year-old subject who received the ur pain that progressed to left-sided Bell's palsy 1 day following

### **Medical Certification** Current COVID 19 Vaccine Considerations

# **THE RISKS**

#### LIST OF 1291 ADVERSE EVENTS OF SPECIAL INTEREST (Released by Pfizer under FOIA):

1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic neuritis; Acquired C1 inhibitor deficiency; Acquired epidermolysis bullosa; Acquired epileptic aphasia: Acute cutaneous lupus ervthematosus: Acute disseminated encephalomyelitis: Acute encephalitis with refractory, repetitive partial seizures; Acute febrile neutrophilic dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute haemorrhagic oedema of infancy; Acute kidney injury; Acute macular outer retinopathy; Acute motor axonal neuropathy; Acute motor-sensory axonal neuropathy; Acute myocardial infarction; Acute respiratory distress syndrome; Acute respiratory failure; Addison's disease;Administration site thrombosis;Administration site vasculitis;Adrenal thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air embolism:Alanine aminotransferase abnormal:Alanine aminotransferase increased:Alcoholic seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune hepatitis; Alopecia areata; Alpers disease; Alveolar proteinosis; Ammonia abnormal; Ammonia increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid shock; Anaphylactoid syndrome of pregnancy; Angioedema; Angiopathic neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibody positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive; Anti-cyclic citrullinated peptide antibody positive; Anti-epithelial antibody positive; Anti-erythrocyte antibody positive; Anti-exosome complex antibody positive; Anti-GAD antibody negative; Anti-GAD antibody positive; Anti-ganglioside antibody positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody positive:Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody positive; Anti-HLA antibody test positive; Anti-IA2 antibody positive; Anti-insulin antibody increased: Anti-insulin antibody positive: Anti-insulin receptor antibody increased: Antiinsulin receptor antibody positive: Anti-interferon antibody negative: Anti-interferon antibody positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle specific kinase antibody positive; Anti-myelin-associated glycoprotein antibodies positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial antibody positive; Anti-neuronal antibody positive; Antineutrophil cytoplasmic antibody increased; Antineutrophil cytoplasmic antibody positive; Anti-neutrophil cytoplasmic antibody positive vasculitis; Anti-NMDA antibody positive; Antinuclear antibody increased; Antinuclear antibody positive; Antiphospholipid antibodies positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin antibody positive; Antiribosomal P antibody positive; Anti-RNA polymerase III antibody positive; Anti-saccharomyces cerevisiae antibody test positive; Anti-sperm antibody positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;Anti-VGKC antibody positive: Anti-vimentin antibody positive: Antiviral prophylaxis: Antiviral treatment; Anti-zinc transporter 8 antibody positive; Aortic embolus; Aortic thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia:Application site thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis

coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-19:Ataxia:Atheroembolism:Atonic seizures:Atrial thrombosis:Atrophic thyroiditis:Atypical benign partial epilepsy; Atypical pneumonia; Aura; Autoantibody positive; Autoimmune anaemia; Autoimmune aplastic anaemia; Autoimmune arthritis; Autoimmune blistering disease:Autoimmune cholangitis:Autoimmune colitis:Autoimmune demvelinating disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eve disorder:Autoimmune haemolytic anaemia;Autoimmune heparin-induced thrombocytopenia:Autoimmune hepatitis:Autoimmune hyperlipidaemia:Autoimmune hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune uveitis; Autoinflammation with infantile enterocolitis; Autoinflammatory disease; Automatism epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating polyneuropathy; Axonal neuropathy; Bacterascites; Baltic myoclonic epilepsy; Band sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein antibody positive; Bickerstaff's encephalitis; Bile output abnormal; Bile output decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe syndrome:Brachiocephalic vein thrombosis:Brain stem embolism:Brain stem thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;Budd-Chiari syndrome;Bulbar palsy;Butterfly rash;Clq nephropathy;Caesarean section;Calcium embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic

tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child-Pugh-Turcotte score abnormal;Child-Pugh-Turcotte score increased; Chillblains; Choking; Choking sensation; Cholangitis sclerosing; Chronic autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue syndrome; Chronic gastritis; Chronic inflammatory demyelinating polyradiculoneuropathy; Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids: Chronic recurrent multifocal osteomyelitis: Chronic respiratory failure; Chronic spontaneous urticaria; Circulatory collapse; Circumoral oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor Cl decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement factor C4 decreased;Complement factor decreased;Computerised tomogram liver abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian syndrome:Congenital herpes simplex infection;Congenital myasthenic syndrome:Congenital varicella infection:Congestive hepatopathy:Convulsion in childhood;Convulsions local:Convulsive threshold lowered:Coombs positive haemolytic anaemia:Coronary artery disease:Coronary artery embolism:Coronary artery thrombosis:Coronary bypass thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus test positive:Corpus callosotomy:Cough:Cough variant asthma:COVID-19:COVID-19 immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute inflammatory syndrome; Death neonatal; Deep vein thrombosis; Deep vein thrombosis postoperative: Deficiency of bile secretion: Deja vu; Demvelinating polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes mellitus:Diabetic ketoacidosis:Diabetic mastopathy:Dialvsis amvloidosis:Dialvsis membrane reaction; Diastolic hypotension; Diffuse vasculitis; Digital pitting scar; Disseminated intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated neonatal herpes simplex; Disseminated varicella; Disseminated varicella zoster vaccine virus infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter pneumonia:Enterocolitis:Enteropathic spondylitis:Eosinopenia:Eosinophilic

### **Medical Certification** Current COVID 19 Vaccine Considerations

# **THE RISKS**

### LIST OF 1291 ADVERSE EVENTS OF SPECIAL INTEREST (Released by Pfizer under FOIA):

fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema multiforme:Erythema nodosum:Evans syndrome:Exanthema subitum:Expanded disability status scale score decreased:Expanded disability status scale score increased:Exposure to communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic seizure:Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset non-motor seizure; Generalised tonic-clonic seizure; Genital herpes; Genital herpes simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis membranoproliferative:Glomerulonephritis membranous:Glomerulonephritis rapidly progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2 gangliosidosis:Goodpasture's syndrome:Graft thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;Guillain-Barre syndrome;Haemolytic anaemia;Haemophagocytic lymphohistiocytosis:Haemorrhage:Haemorrhagic ascites:Haemorrhagic

disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic vasculitis;Hantavirus pulmonary infection;Hashimoto's

encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch-Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus

infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation; Herpetic radiculopathy; Histone antibody positive; Hoigne's syndrome; Human herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human herpesvirus 7 infection;Human herpesvirus 8 infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated adverse reaction; Immune-mediated cholangitis; Immune-mediated cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy:Immune-mediated endocrinopathy:Immune-mediated enterocolitis:Immunemediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis: Immune-mediated myositis: Immune-mediated nephritis: Immune-mediated neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective thrombosis:Inflammation:Inflammatory bowel disease:Infusion site thrombosis:Influsion site vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive; IPEX syndrome; Irregular breathing; IRVAN syndrome; IVth nerve paralysis; IVth nerve paresis; JC polyomavirus test positive; JC virus CSF test positive; Jeavons syndrome; Jugular vein embolism; Jugular vein thrombosis; Juvenile idiopathic arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's excrescences;Larvngeal dyspnoea;Larvngeal oedema;Larvngeal rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia neonatal:Lewis-Sumner syndrome:Lhermitte's sign:Lichen planopilaris:Lichen planos:Lichen sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test abnormal;Liver function test decreased;Liver function test increased;Liver induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration

infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection neurological:Herpes zoster meningitis:Herpes zoster meningoencephalitis:Herpes zoster meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human herpesvirus 7 infection;Human herpesvirus 8 infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated adverse reaction;Immune-mediated cholangitis;Immune-mediated cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy: Immune-mediated endocrinopathy: Immune-mediated enterocolitis: Immunemediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis; Immune-mediated myositis; Immune-mediated nephritis; Immune-mediated neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder:Immune-mediated thyroiditis:Immune-mediated uveitis:Immunoglobulin G4 related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site vasculitis:Injection site thrombosis:Injection site urticaria:Injection site vasculitis:Instillation site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive; IPEX syndrome; Irregular breathing; IRVAN syndrome; IVth nerve paralysis; IVth nerve paresis; JC polyomavirus test positive; JC virus CSF test positive; Jeavons syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic arthritis; Juvenile myoclonic epilepsy; Juvenile polymyositis; Juvenile psoriatic arthritis; Juvenile spondyloarthritis; Kaposi sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase increased:Leukoencephalomvelitis:Leukoencephalopathy:Leukopenia:Leukopenia neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test abnormal;Liver function test decreased;Liver function test increased;Liver induration:Liver injury:Liver iron concentration abnormal:Liver iron concentration

### **Medical Certification** Current COVID 19 Vaccine Considerations

# **THE RISKS**

### LIST OF 1291 ADVERSE EVENTS OF SPECIAL INTEREST (Released by Pfizer under FOIA):

neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;Paget-Schroetter syndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatous dermatitis;Palmoplantar keratoderma;Palpable

purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxical embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial seizures; Partial seizures with secondary generalisation; Patient isolation; Pelvic venous thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis lupus:Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune syndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune syndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgia rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure increased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural hypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post stroke epilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral fatigue syndrome:Postictal headache:Postictal paralysis:Postictal psychosis:Postictal state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy syndrome:Post-traumatic epilepsy:Postural orthostatic tachycardia syndrome:Precerebral artery thrombosis; Pre-eclampsia; Preictal state; Premature labour; Premature menopause:Primary amyloidosis:Primary biliary cholangitis:Primary progressive multiple sclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availability issue;Product distribution issue;Product supply issue;Progressive facial hemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiple sclerosis; Progressive relapsing multiple sclerosis; Prosthetic cardiac valve thrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriatic arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary oil microembolism; Pulmonary renal syndrome; Pulmonary sarcoidosis; Pulmonary sepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis

brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen encephalitis;Raynaud's phenomenon;Reactive capillary endothelial proliferation;Relapsing multiple sclerosis; Relapsing-remitting multiple sclerosis; Renal amyloidosis; Renal arteritis:Renal artery thrombosis:Renal embolism:Renal failure:Renal vascular thrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory arrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratory paralysis; Respiratory syncytial virus bronchiolitis; Respiratory syncytial virus bronchitis:Retinal artery embolism:Retinal artery occlusion:Retinal artery thrombosis:Retinal vascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinol binding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitoneal fibrosis; Reversible airways obstruction; Reynold's syndrome; Rheumatic brain disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoid factor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoid neutrophilic dermatosis; Rheumatoid nodule; Rheumatoid nodule removal; Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO syndrome:Sarcoidosis:SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test positive:SARS-CoV-2 antibody test:SARS-CoV-2 antibody test negative:SARS-CoV-2 antibody test positive; SARS-CoV-2 carrier; SARS-CoV-2 sepsis; SARS-CoV-2 test; SARS-CoV-2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARS-CoV-2 test positive:SARS-CoV-2 viraemia:Satovoshi syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated digital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary amyloidosis;Secondary cerebellar degeneration;Secondary progressive multiple sclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure like phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septic pulmonary embolism; Severe acute respiratory syndrome; Severe myoclonic epilepsy of infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silent thyroiditis;Simple partial seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody positive; Sneezing; Spinal artery embolism; Spinal artery thrombosis; Splenic artery thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein thrombosis; Spondylitis; Spondyloarthropathy; Spontaneous heparin-induced thrombocytopenia syndrome:Status epilepticus;Stevens-Johnson syndrome:Stiff leg syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site vasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained death in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic ophthalmia:Systemic lupus erythematosus:Systemic lupus erythematosus disease activity index abnormal;Systemic lupus erythematosus disease activity index decreased;Systemic lupus erythematosus disease activity index increased;Systemic lupus erythematosus rash;Systemic scleroderma;Systemic sclerosis pulmonary; Tachycardia; Tachypnoea; Takayasu's arteritis; Temporal lobe epilepsy; Terminal ileitis; Testicular autoimmunity; Throat tightness; Thromboangiitis obliterans; Thrombocytopenia; Thrombocytopenic purpura; Thrombophlebitis; Thrombophlebitis migrans; Thrombophlebitis

neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody positive; Thrombosis; Thrombosis corpora cavernosa; Thrombosis in device; Thrombosis mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic stroke: Thrombotic thrombocytopenic purpura; Thyroid disorder; Thyroid stimulating immunoglobulin increased; Thyroiditis; Tongue amyloidosis; Tongue biting; Tongue oedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile acids increased; Toxic epidermal necrolysis; Toxic leukoencephalopathy; Toxic oil syndrome: Tracheal obstruction: Tracheal oedema: Tracheobronchitis: Tracheobronchitis mycoplasmal:Tracheobronchitis viral:Transaminases abnormal:Transaminases increased;Transfusion-related alloimmune neutropenia;Transient epileptic amnesia; Transverse sinus thrombosis; Trigeminal nerve paresis; Trigeminal neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosis complex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type I hypersensitivity;Type III immune complex mediated reaction;Uhthoff's phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord thrombosis:Uncinate fits;Undifferentiated connective tissue disease;Upper airway obstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urine increased:Urticaria:Urticaria papular:Urticarial vasculitis:Uterine rupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerve paralysis; Varicella; Varicella keratitis; Varicella post vaccine; Varicella zoster gastritis; Varicella zoster oesophagitis; Varicella zoster pneumonia; Varicella zoster sepsis; Varicella zoster virus infection; Vasa praevia; Vascular graft thrombosis; Vascular pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic rash:Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava embolism: Vena cava thrombosis: Venous intravasation: Venous recanalisation: Venous thrombosis; Venous thrombosis in pregnancy; Venous thrombosis limb; Venous thrombosis neonatal; Vertebral artery thrombosis; Vessel puncture site thrombosis; Visceral venous thrombosis; VIth nerve paralysis; VIth nerve paresis; Vitiligo; Vocal cord paralysis; Vocal cord paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White nipple sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated Guillain Barre syndrome.

#### PFIZER REPORTED 1291 ADVERSE EVENTS of SPECIAL INTEREST



### Medical Certification and Disability Current COVID 19 Vaccine Considerations

If you are sick or injured by the vaccines or for any other reason and remain so for 6 months or more, then you are probably protected against discrimination per the Americans with Disabilities Act or Rehabilitation Act of 1973

Anti-discrimination provisions prohibit employers from reprimanding, punishing or terminating employees based on their disability

Employers must provide Reasonable Accommodation to disabled employees, whether they are contracted or engaged full or part-time and regardless of the cause of their disability.

See: <u>https://www.ada.gov/pubs/adastatute08.htm</u>



### SUMMARY

Many aviation professionals also sought guidance from civil aviation regulators. These regulators are ultimately responsible for the safe and secure transport of people, yet most if not all actively ignored their own safety recommendations against unproven, unapproved drug use by flight crews. Transport Canada, for instance, simply removed this online guidance the week following numerous written and pointed questions regarding same. Once airlines mandated vaccination, many pilots steadfastly refused based on risk and were subsequently put on unpaid leave or outright terminated. Principled professionals were forced out of aviation and the industry lost hundreds of thousands of hours of experience. Now, the global airline industry is heading into a dire staffing crisis.

Thousands of other pilots were coerced into vaccination to provide for their families. This has taken a toll on their mental health and performance. As sobering as all of this is, it merely set the stage for what we are now witnessing: a landscape which should greatly concern airlines and the travelling public.



## SUMMARY

Scientists and doctors are hearing daily from hundreds of vaccine-injured airline pilots. These harms include cardiovascular issues, blood clots, neurological and auditory issues, to name just a few. Many of our pilots have lost medical certification to fly and may not recover the same. Others are continuing to pilot aircraft while carrying symptoms that should be declared and investigated, creating a human factors hazard of unprecedented breadth.

The very foundation of the commercial aviation culture non-punitive reporting - no longer exists. Aviation professionals have suffered and are suffering medical issues that appear to correlate to receipt of Covid-19 vaccinations. Their current spectrum of symptoms is broad, ranging nuisance to death and some adverse reactions may only manifest over time. There have been no long-term studies on any of these shots; vaccine health risks, clinical trial fraud, poor practice and insignificant efficacy continues to mount.



### SUMMARY

The Pfizer documents released under FOIA combined with FDA, MHRA and EMA regulatory documentation show that essential safety and efficacy information has been withheld from the public, and that the scope of regulatory oversight and testing requirements is inadequate. Worse, there appears to be no evidence of aviation regulators, airlines or unions having performed any of their own due diligence into Covid-19 vaccines and the impact on aviator or crew health or performance. This is at complete odds with existing aviation medical standards.

Questions exist around competence and possible negligence. Failure to address this potential medical watershed will make the airlines and unions complicit in a culture shift that has rocked the aviation mantra of "safety first, always". The airlines and unions represented have been encouraged to assist and warned of dire repercussions, repeatedly.

To date there has been little meaningful action, and in many cases nothing but stone-walling and silence.

There is a saying in aviation, "If there's doubt, there is no doubt." New data raises significant concerns over the safety or efficacy of the Covid-19 vaccines and their long-term effects. There should therefore be no further doubt in aviation. Safety must return to the fore.

## **CALL TO ACTION**

Civil aviation authorities such as the Federal Aviation Administration, Transport Canada, UK Civil Aviation Authority and European Union Aviation Safety Agency must begin fulfilling their regulatory obligations.

The crisis in pilot health must be publicly addressed by airlines and representing unions.

This is a CALL TO ACTION FOR:

- Where it exists, mandated Covid-19 vaccination for aviation workers **must cease**. At the minimum, a SAFETY HOLD must be mandated to institute this AEROSPACE SAFETY PROTOCOL INITIATIVE, which screens all medical certificate holders (including controllers) to ensure they have not suffered vaccine injuries.
- A permissive environment for self-reporting (SEE AC 120-82) needs to be reemphasized by regulators and airlines.
- Pro-active investigation through medical screening of pilots and cabin crew needs to be a high priority, focusing on high prevalence side effects which are now showing up in the general public and in many of our vaccinated aviation professionals.
- Airlines and regulators hold data about sickness and medical certificate suspension, including symptoms and causal reasons. This data should be analyzed by independent third parties to establish or rule out Covid-19 vaccination as a possible cause.

## **SCREENING PROCESS**

(Examples of symptoms-based and pro-active screening process)

CLINICAL SYMPTOMS: dizziness, vertigo, impaired balance WORK UP: CT Temporal Bone, high-resolution, 3 Tesla MRI brain, with and without contrast, WITH Internal Auditory Canal (IAC) - Protocol and attention to posterior fossa structures, INFLAMMATORY MARKERS -CRP-hs Fibrinogen D-Dimer ADDITIONAL (Per Findings): Neuro Consult post findings of Neuroradiologist

CLINICAL SYMPTOMS: chest pain, palpitations, arrythmias WORK UP: Cardiac MRI for morphology and function, with late-phase gadolinium enhancement to assess for myocarditis, pericarditis, EKG, INFLAMMATORY MARKERS - CRP-hs Fibrinogen D-Dimer Troponin-1

ADDITIONAL (Per Findings): Cardiology Consult


CLINICAL SYMPTOMS: shortness of breath, dyspnea on exertion WORK UP: CT Angiogram of Lung with arterial and venous phases to evaluate for peripheral microthrombi and/or larger pulmonary emboli, INFLAMMATORY MARKERS - CRP-hs Fibrinogen D-Dimer ADDITIONAL (Per Findings): Internal Medicine, Pulmonology Consult

# **OTHER CONSIDERATIONS FOR SCREENING**

(When required per initial findings)

- Comprehensive Metabolic Profile Cholesterol
   profile
- Glycosylated hemoglobin Fasting insulin
- CBC with differential Vitamin B12, Folate
- Vitamin B6 and B1 25-OH Vitamin D
- Magnesium (serum and RBC) Zinc
- ENDOCRINE TESTS Draw in AM prior to any meds to assess damage to endocrine system
- FSH, LH, Estradiol, Progesterone, Testosterone (free and total), DHEA-S, DHEA
- TSH (hs), Free T3 and Free T4, Anti-microsomal, Anti-thyroglobulin AB
- 8 AM Cortisol, total and free, Prolactin, Parathyroid Hormone, Amylase, Lipase
- PSA, CA125, CA 19-9, CEA, CA 15-9

- INFLAMMATORY MARKERS and SPECIALTY TESTS:
- CRP-hs Fibrinogen D-Dimer Troponin-1
- Ferritin Cytokine Panel IL-6, IL-10 Myeloperoxidase (MPO)
- 24-hour urine for measure of: catecholamines, metanephrines, VMA
- To assess new infections:
- SARS-CoV-2 spike protein antibodies
- SARS-CoV-2 Nucleocapsid Antibodies
- Mycoplasma pneumoniae, EBV titers, CMV titers, RSV titers
- HIV and other viral titers as indicated by presenting symptoms.
- G6PD



## **SOURCES** and **REFERENCES**

The COVID-19 Vaccine Safety Surveillance: Active Monitoring Master Protocol

https://bestinitiative.org/wp-content/uploads/2021/02/C19-Vaccine-Safety-Protocol-2021.pdf

https://www.faa.gov/ame\_guide/pharm/dni\_dnf

750+ Studies About the Dangers of the COVID-19 Injections

#### TRUTH FOR HEALTH VACCINE INJURY TREATMENT GUIDE.

https://www.truthforhealth.org/2022/04/vaccine-injury-treatment-guide-your-roadmap-torecovery/

#### GLOBAL COALITION STATEMENT: COMMERCIAL PILOT VACCINE INJURIES.

https://gaacoalition.substack.com/

LTC Theresa M. Long, MD, MPH, FS https://rumble.com/voz7ik-theresa-long-md-mph-the-vaccine-is-a-greater-threat-tosoldiers-and-defense.html

#### **DMED Data**

https://www.youtube.com/watch?v=Lt7QzetfRSQ




#### **NEAR MISS – Vaccine Injured Pilot**

https://rumble.com/voz514-cody-flint-i-have-missed-an-entire-year-of-my-life-trapped-in-vaccine-injur.html

#### https://www.ada.gov/pubs/adastatute08.htm

#### https://www.faa.gov/documentLibrary/media/Advisory\_Circular/AC\_120-82.pdf





## CONCLUSION

Today, we have a unique opportunity to salvage our aviation industry and traveling society through local action in defiance of political appointees and myopic federal policy-makers who refuse to recognize the consequences of their illegal 'vaccine" mandates; which have injured or killed millions of people around the world. Worse, the evidence is now abundantly clear that all of these shots were experimental, rushed and ill-advised, even by the FDA's internal review committee prior to the Emergency Use Authorization.

Given that our governments have failed in their obligations to protect their citizens and in some cases, participated in the genocide in progress, our only solution is for each of us to help others by applying common sense collaboration and using the laws already in existence to preserve the enormous commercial, private and national security tool that we all call the aviation industry.

We are not getting any help from any government and we're not going to. Our safety and our destiny is in our hands to preserve our society, life and way of living. We must all collaborate to identify the risks, help people mitigate those risks and get the aviation community back into full operation as it was prior to Covid.

Collaboration among all interested parties is the key and even the flying public can help by insisting on these safety measures and demanding that airlines ensure at least one un-vaccinated pilot is on every flight; and with access to the controls of the aircraft. Sitting behind a locked cockpit door will not help when there is an in-flight emergency.

Medical Certificate holders are already facing recurrent certifications by their respective flight surgeons and this collaborative effort is designed to help vaccine-injured people understand their risks, repair their injuries and keep our society, goods and services freely moving around the world

### QUESTIONS

CDC, NIH, Pharmaceutical Profits  $\rightarrow$ FDA, FAA, AMEs  $\rightarrow$ 

Fear, Political Pressure to Conform  $\rightarrow$ 

Violation of Do Not Issue policy  $\rightarrow$ 

